Group 1 - The core viewpoint of the article highlights the recent strong performance of several biopharmaceutical stocks, particularly in the Hong Kong market, with innovative drug concepts becoming increasingly active [1] - WuXi AppTec (药明合联) led the sector with a rise of over 8%, while WuXi Biologics (药明生物) increased by over 5%, and other companies like CanSino Biologics (康方生物), Genscript Biotech (云顶新耀), and Innovent Biologics (诺诚健华) saw gains exceeding 4% [1] - According to Guolian Minsheng Securities, the innovative drug business development (BD) transactions in China are expected to continue the high growth trend seen in 2025, indicating a robust upward momentum in the industry [1] Group 2 - The stock performance data shows that WuXi AppTec (02268) increased by 8.40% to a latest price of 63.250, with a total market capitalization of 795.68 billion [2] - WuXi Biologics (02269) rose by 5.38% to 40.340, with a market cap of 1,669.08 billion, reflecting a year-to-date increase of 28.31% [2] - Other notable performers include CanSino Biologics (09926) up by 4.81%, Genscript Biotech (01952) up by 4.27%, and Innovent Biologics (69660) up by 4.04%, indicating a positive trend across the sector [2]

Group 1 - The core point of the article is that Shijiazhuang Pharmaceutical Group announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for 230 million yuan, after which the company will no longer hold any shares in the firm [1] - The transaction price was slightly above the assessed value of 226 million yuan, which was based on an independent evaluation with a total equity value of 753 million yuan for Guoxin Huijin as of June 30, 2025 [1] - Guoxin Huijin's main business is in the full media communication sector, specifically mobile financial information services, which is not a core area for Shijiazhuang Pharmaceutical [1] Group 2 - The financial data indicates that Guoxin Huijin is projected to generate revenue of 42.52 million yuan in 2025, with a net loss of 26.94 million yuan, including a loss of 15.72 million yuan in the second half of the year [1] - The purpose of the sale is to optimize resource allocation and focus on the core pharmaceutical business, with proceeds intended to supplement the daily operating funds of Shijiazhuang Pharmaceutical [1] - The company expects to record a loss of approximately 15 million yuan from this transaction, calculated as the difference between the transaction price and the book value of the investment [1]

Market Performance - The Hong Kong stock market saw a significant afternoon rally, with the Hang Seng Index rising over 1%, the Hang Seng Tech Index increasing nearly 1%, and the National Enterprises Index up by 0.74% [1] Leading Stocks - New World Development Company Limited (00016) led the gains with a rise of 6.02%, marking a year-to-date increase of 52.59% and a total market capitalization of 418.73 billion [2] - WuXi Biologics (02269) increased by 4.81%, with a year-to-date rise of 27.61% and a market cap of 165.99 billion [2] - CSPC Pharmaceutical Group (01093) saw a 3.67% increase, with a year-to-date gain of 17.32% and a market capitalization of 113.96 billion [2] - WuXi AppTec (02359) rose by 3.04%, with a year-to-date increase of 20.36% and a total market value of 354.47 billion [2] - NetEase (099999) increased by 2.74%, but has a year-to-date decline of 16.22%, with a market cap of 569.25 billion [2] - Trip.com Group (09961) rose by 2.60%, with a year-to-date decline of 25.85% and a market capitalization of 268.5 billion [2] - Tencent Holdings (00700) increased by 2.34%, with a year-to-date decline of 12.52% and a market cap of 4.77 trillion [2] - ZTO Express (09992) rose by 2.32%, with a year-to-date increase of 17.07% and a market capitalization of 149.97 billion [2] - Pop Mart International (09992) increased by 2.31%, with a year-to-date rise of 22.75% and a market cap of 309.09 billion [2] - Mengniu Dairy (02319) rose by 2.10%, with a year-to-date increase of 7.65% and a market capitalization of 62.26 billion [2]

Core Viewpoint - The Hong Kong Dividend ETF (ICBC, 159691) has experienced significant net redemptions, indicating a trend of outflows from the fund, which may reflect investor sentiment and market conditions [1][2]. Group 1: Fund Performance - On February 26, the Hong Kong Dividend ETF (ICBC, 159691) faced a net redemption of 69.2 million yuan, ranking 4th out of 217 in cross-border ETF net outflows for the day [1]. - Over the past five days, the fund has seen net redemptions totaling 123 million yuan, ranking 2nd out of 217 [1]. - The fund's total size as of February 26 is 8.549 billion yuan, down from 8.78 billion yuan the previous day, with the outflow representing 0.79% of the prior day's size [1]. Group 2: Fund Details - The Hong Kong Dividend ETF (ICBC, 159691) was established on March 30, 2023, with an annual management fee of 0.45% and a custody fee of 0.07% [2]. - As of February 26, the fund has 6.134 billion shares outstanding, a decrease of 6.06% from 6.53 billion shares on December 31, 2025, while the fund's size has increased by 1.35% during the same period [2]. Group 3: Trading Activity - The cumulative trading amount for the Hong Kong Dividend ETF over the last 20 trading days is 6.993 billion yuan, with an average daily trading amount of 350 million yuan [2]. - Year-to-date, the fund has recorded a cumulative trading amount of 10.928 billion yuan over 33 trading days, averaging 331 million yuan per day [2]. Group 4: Fund Holdings - The current fund managers are Zhao Xu and Jiao Wenlong, both managing the fund since February 5, 2026, with a return of 1.12% during their tenure [3]. - Major holdings in the fund include China National Offshore Oil Corporation (14.55%), China Shenhua Energy (9.65%), and China Pacific Insurance (8.90%), among others, with significant market values [3].

Core Insights - The introduction of PD-1 inhibitors in 2014 marked a significant turning point in the fight against cancer, with Bristol-Myers Squibb's Opdivo and Merck's Keytruda leading the charge in immunotherapy [1][3] - The competition between Opdivo and Keytruda has evolved over the years, with Keytruda ultimately becoming the top-selling drug globally by 2024 [21][22] Historical Context - The history of cancer immunotherapy began with William Coley's discovery in the late 19th century, which was followed by a long period of stagnation until the late 20th century when key immune cells were identified [4] - The discoveries of James Allison and Tasuku Honjo regarding CTLA-4 and PD-1, respectively, laid the groundwork for the development of PD-1 inhibitors [5][10] Drug Development - Opdivo was developed with strong backing from Bristol-Myers Squibb after acquiring Medarex in 2009, leading to its approval in Japan in 2014 [12] - Keytruda's development faced initial setbacks but was revitalized by Merck's strategic decision to conduct an unprecedented "super I phase" trial, leading to its approval shortly after Opdivo [14][15][16] Market Dynamics - In 2016, a critical competition occurred between Opdivo and Keytruda in the non-small cell lung cancer (NSCLC) market, which is the largest segment in oncology [17] - BMS's failure in the CheckMate-026 trial led to a significant drop in Opdivo's market position, while Merck's more selective approach in the KEYNOTE-024 trial resulted in Keytruda's success [18][19][20] Sales Performance - By 2024, Keytruda's sales reached $29.5 billion, marking an 18% increase and solidifying its position as the top-selling drug globally [21] - Opdivo, while still a major player, saw its sales decline but remained above the $10 billion mark, maintaining its status as a heavyweight in the market [22][23] Competitive Landscape - The global PD-1 inhibitor market is highly competitive, with 527 candidates in development as of early 2025, including 20 approved drugs [26][29] - In China, the market is characterized by intense competition among local manufacturers, with significant price reductions due to national healthcare negotiations [30][31] Future Outlook - Keytruda's core patent is expected to expire in 2028, potentially leading to a significant drop in sales as biosimilars enter the market [32] - A new challenger, Ivonescimab, has shown superior efficacy compared to Keytruda in clinical trials, indicating a shift towards dual-target therapies in cancer treatment [33][35]

Core Viewpoint - The company Shiyao Group (01093) announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for RMB 230 million, which will allow the company to focus on its core business and optimize its resource allocation and financial structure [1] Group 1 - The seller, Shiyao Innovation Pharmaceutical Co., Ltd., is a non-wholly owned subsidiary of Shiyao Group [1] - The transaction is expected to help the seller concentrate on its core business and reduce operational risks, leading to high-quality development [1] - The target company primarily operates a full-media communication business, which is not part of the seller's core operations [1]

Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group (石药集团), has announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for RMB 230 million, which will allow the company to focus on its core business and optimize its financial structure [1]. Group 1 - The seller, Shijiazhuang Pharmaceutical Innovation Co., Ltd., is a non-wholly owned subsidiary of the company [1]. - The transaction is based on a comprehensive consideration of the seller's actual development status [1]. - The sale is expected to help optimize the seller's resource allocation and financial structure, allowing for a focus on core business and reduction of operational risks [1]. Group 2 - The target company primarily operates a full-media communication business platform, which is not part of the seller's core business [1]. - After the completion of the sale, the seller and the group will no longer hold any equity in the target company [1]. - This move is anticipated to contribute to the overall benefit of the group and facilitate high-quality development [1].

Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group, announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for RMB 230 million, aiming to optimize resource allocation and focus on core business operations [1] Group 1 - The seller, Shijiazhuang Pharmaceutical Innovation Co., Ltd., is a non-wholly owned subsidiary of the company [1] - The transaction is expected to enhance the seller's financial structure and reduce operational risks [1] - The target company primarily operates in the full media communication business, which is not part of the seller's core operations [1] Group 2 - The completion of the sale will result in the seller and the group no longer holding any equity in the target company [1] - The decision to sell was based on a comprehensive assessment of the seller's actual development status [1] - This move is anticipated to facilitate high-quality development for the seller and benefit the overall group [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 關連交易 出售目標公司的30.0704%股權 出售事項 於 2026 年 2 月 25 日， 賣 方（ 本 公司 非 全 資附 屬 公 司 ）與 買方 訂 立 股權 轉 讓 協議 ， 內 容有 關 買賣目標公司的30.0704 % 股權，代價為人民幣230,000,000元。於出售事項完成後，賣方 及本集團將不再持有目標公司的任何股權。 上市規則的涵義 買 方 為 本 公 司 董 事 及 主 要 股 東 蔡 東 晨 先 生 的 聯 繫 人 ， 故 為 上 市 規 則 第 14A 章 項 下 本 公 司 的關連人士。因此，出售事項構成本公司於上市規則第14A章項下的關連交易。 由於上市規則第14.07條所載有關出售事項的一項或多項適用百分比率超過0.1 ...

Investment Rating - The report assigns an "Accumulate" rating to the company [1][6]. Core Insights - The report highlights the strong innovation and R&D capabilities of the company, which is entering a harvest period for innovative drugs and has established an international business development ecosystem with several significant licensing agreements [2][10]. - The company is expected to achieve a significant increase in EPS from 0.37 in 2024 to 0.75 in 2025, with a projected growth rate of 48% [10]. - The target price for the company is set at 16.58 HKD, reflecting a favorable valuation based on comparable company analysis [10]. Financial Summary - Total revenue is projected to be 31,450.11 million RMB in 2023, with a slight increase of 1.7% [4]. - Net profit is expected to decrease by 3.6% in 2023, followed by a significant recovery of 47.5% in 2025 [4]. - The company’s PE ratio is forecasted to decrease from 18.26 in 2023 to 12.34 in 2026, indicating an improving valuation over time [4]. Pipeline Overview - The company has a leading position in the oncology pipeline, particularly with SYS6010, which is the fastest progressing EGFR ADC globally, with multiple early-stage assets expected to report data in 2026 [10][16]. - In the weight loss and metabolic areas, the company has established a leading position domestically and has signed a strategic collaboration with AstraZeneca for the development of innovative long-acting peptide drugs [10][24]. - The company has a robust pipeline in the small nucleic acid technology sector, positioning it as a leader in the domestic siRNA market [10][24]. Business Development and International Strategy - The company is making steady progress in its international strategy, with ongoing collaborations with AstraZeneca and other multinational corporations, reflecting its competitive edge in innovative drug development [10][24]. - The company is expected to continue achieving external licensing agreements, with over 20 innovative drug assets entering clinical stages annually [10][24].